Korean Medicine Expands Globally... National Institute for Korean Medicine Development Holds "Korean Medicine Industry Full-Cycle Performance Exchange Meeting"

Published 07 Nov.2024 19:11(KST)

Updated 02 Aug.2025 16:16(KST)

open/close

Special Lectures on Technology, Achievement Presentations, and Discussions
Opportunities to Promote Exchange Among Companies

The National Institute for Korean Medicine Development held the "2024 Korean Medicine Industry Full-Cycle Support System Establishment Project Performance Exchange Meeting" at Le Meridien Hotel in Jung-gu, Seoul on November 7.

This exchange meeting was organized to establish a practical cooperation system among companies related to Korean medicine and to share achievements, focusing on topics such as "technology value assessment and case studies" and "marketing strategies for overseas expansion projects" that are essential for business operations.

In particular, 24 companies in the Korean medicine sector-including those specializing in herbal preparations, Korean medicine convergence, and Korean medical devices-participated and discussed the challenges they face in the industry and potential solutions. Outstanding Korean medicine companies, Bichedam and IamtheW, presented their achievements gained through technological innovation, highlighting the future potential of the Korean medicine industry.

Moon Hobin, CEO of Bichedam, stated, "Through collaboration with the National Institute for Korean Medicine Development, we are developing BCD101, a treatment for isolated systolic hypertension (ISH) in the elderly that ensures both safety and efficacy. We ask for your continued interest and support so that we can grow into an innovative bio-pharmaceutical company based on natural substances."

Shin Jesu, Acting President of the National Institute for Korean Medicine Development, said, "This performance exchange meeting reaffirmed the importance of technological exchange and cooperation among companies in the Korean medicine industry. We will continue to do our utmost to vitalize the Korean medicine industry and promote its expansion and globalization in the global market through support for product and technology development."